4-(6-trifluoromethyl-pyridin-3-yl)-benzoic acid | 845826-95-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-(6-trifluoromethyl-pyridin-3-yl)-benzoic acid
• 英文别名: 4-[6-(trifluoromethyl)-pyridin-3-yl]benzenecarboxylic acid；4-(6-(Trifluoromethyl)pyridin-3-yl)benzoic acid；4-[6-(trifluoromethyl)pyridin-3-yl]benzoic acid
• CAS: 845826-95-1
• 化学式: C₁₃H₈F₃NO₂
• 分子量: 267.207
• InChiKey: FOOREMKGBPKDRA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  6

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  4-(6-trifluoromethyl-pyridin-3-yl)-benzoic acid 、 2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-amine 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 生成 N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-[6-(trifluoromethyl)-pyridin-3-yl]benzamide
  参考文献：
  名称：

  Discovery of imidazo[1,2-a]pyridines as potent MCH1R antagonists

  摘要：

  A series of imidazo[1,2-a] pyridine derivatives was identified and evaluated for MCH1R binding and antagonistic activity. Introduction of a methyl substituent at the 3-position of imidazo[1,2-a] pyridine provided compounds with a significant improvement in MCH1R affinity. Representative compounds in this series exhibited good potency and brain exposure in rats. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.06.101
• 作为产物：
  描述：

  4-(6-trifluoromethyl-pyridin-3-yl)-benzoic acid methyl ester 在 lithium hydroxide 、 水 作用下， 以 四氢呋喃 为溶剂， 生成 4-(6-trifluoromethyl-pyridin-3-yl)-benzoic acid
  参考文献：
  名称：

  [EN] HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES
  [FR] AGENTS RECEPTEURS DE L'HISTAMINE H3, PREPARATION ET UTILISATIONS THERAPEUTIQUES

  摘要：

  本发明公开了具有组合物(I)或其药学上可接受的盐的新颖化合物，其具有组胺H3受体拮抗剂或逆激动剂活性，以及制备这种化合物的方法。在另一实施例中，本发明公开了包含组合物(I)的药物组合物，以及使用它们治疗肥胖、认知缺陷、嗜睡症和其他组胺H3受体相关疾病的方法。

  公开号：

  WO2005097740A1

文献信息

• [EN] HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES<br/>[FR] AGENTS RECEPTEURS DE L'HISTAMINE H3, PREPARATION ET UTILISATIONS THERAPEUTIQUES
  申请人：LILLY CO ELI

  公开号：WO2005097740A1

  公开（公告）日：2005-10-20

  The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases

  本发明公开了具有组合物(I)或其药学上可接受的盐的新颖化合物，其具有组胺H3受体拮抗剂或逆激动剂活性，以及制备这种化合物的方法。在另一实施例中，本发明公开了包含组合物(I)的药物组合物，以及使用它们治疗肥胖、认知缺陷、嗜睡症和其他组胺H3受体相关疾病的方法。
• Discovery of quinolone derivatives as antimycobacterial agents
  作者：Kun-Lin Liu、Fei Teng、Lu Xiong、Xiao Li、Chao Gao、Luo-Ting Yu

  DOI：10.1039/d0ra09250a

  日期：——

  6b21: MIC against M. tb H₃₇Rv = 1.2 μg mL⁻¹, MIC against drug-resistant strains = 0.9 μg mL⁻¹, solubility = 132 μg mL⁻¹, non-cytotoxicity.

  6b21：对H37Rv结核分枝杆菌的最小抑菌浓度为1.2 μg/mL，对耐药菌株的最小抑菌浓度为0.9 μg/mL，溶解度为132 μg/mL，无细胞毒性。
• Imidazopyridine Derivatives
  申请人：Kishino Hiroyuki

  公开号：US20080200494A1

  公开（公告）日：2008-08-21

  The invention provides imidazopyridine derivatives represented by the general formula [I] [in which R 1 and R 2 may be the same or different and stand for C 1-6 alkyl or the like, R 3 and R 4 stand for hydrogen atom, methyl group or the like, W stands for mono- or bi-cyclic 3- to 8-membered aromatic or aliphatic heterocycle or the like, and Ar stands for optionally substituted aromatic heterocycle or the like]. These compounds act as melanin-concentrating hormone receptor antagonist and are useful as medicines for central nervous system disorders, cardiovascular system disorders and metabolic disorders.

  该发明提供了由通式[I]表示的咪唑吡啶衍生物 [其中R1和R2可能相同或不同，且代表C1-6烷基或类似物，R3和R4代表氢原子，甲基基团或类似物，W代表单环或双环的3-8元芳香或脂肪杂环或类似物，Ar代表可选择取代的芳香杂环或类似物]。这些化合物作为黑色素浓集激素受体拮抗剂，可用于治疗中枢神经系统疾病、心血管系统疾病和代谢性疾病的药物。
• Imidazopyridine derivatives
  申请人：Banyu Pharmaceuticals, Co., Ltd.

  公开号：US07504412B2

  公开（公告）日：2009-03-17

  The invention provides imidazopyridine derivatives represented by the general formula [I] [in which R1 and R2 may be the same or different and stand for C1-6 alkyl or the like, R3 and R4 stand for hydrogen atom, methyl group or the like, W stands for mono- or bi-cyclic 3- to 8-membered aromatic or aliphatic heterocycle or the like, and Ar stands for optionally substituted aromatic heterocycle or the like]. These compounds act as melanin-concentrating hormone receptor antagonist and are useful as medicines for central nervous system disorders, cardiovascular system disorders and metabolic disorders.

  本发明提供了由通式[I]表示的咪唑吡啶衍生物 [其中R1和R2可以相同或不同，代表C1-6烷基或类似物，R3和R4代表氢原子，甲基基团或类似物，W代表单环或双环3-8成员的芳香或脂肪族杂环或类似物，Ar代表可选取代的芳香杂环或类似物]。这些化合物作为黑素浓聚激素受体拮抗剂，并且可用于治疗中枢神经系统疾病、心血管系统疾病和代谢性疾病的药物。
• Histamine H3 receptor agents, preparation and therapeutic uses
  申请人：Eli Lilly and Company

  公开号：US08008301B2

  公开（公告）日：2011-08-30

  The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, which have histamine—H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor—related diseases

  本发明揭示了式（I）的新化合物或其药学上可接受的盐，其具有组胺-H3受体拮抗剂或反向激动剂活性，以及制备这种化合物的方法。在另一种实施方式中，本发明揭示了包含式（I）化合物的药物组合物，以及使用它们治疗肥胖症、认知缺陷、嗜睡症和其他组胺H3受体相关疾病的方法。